How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?

References

• Anderson J R, Armitage J O, Weisenburger D D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717–720
   PubMed Web of Science ®Google Scholar
• Chiu B C, Weisenburger D D. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4: 161–168
   PubMedGoogle Scholar
• Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Eng J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Ardeshna K M, Smith P, Norton A, Hancock B W, Hoskin P J, MacLennan K A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. British National Lymphoma Investigation. Lancet 2003; 362: 516–522
   PubMed Web of Science ®Google Scholar
• Montoto S, Canals C, Rohatiner A Z, Taghipour G, Sureda A, Schmitz N, et al. (EBMT Lymphoma Working Party). Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; Nov 21: 2324–2331
   PubMed Web of Science ®Google Scholar
• Gandhi M K, Marcus R E. Follicular lymphoma: time for a re-think?. Blood Rev 2005; May 19: 165–178
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R, et al. Follicular lymphoma International Prognostic Index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W, et al. Prediction of survival in follicular lymphoma based on molecular features of tumour-infiltrating immune cells. N Eng J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox B C, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957–2964
   PubMed Web of Science ®Google Scholar
• Glas A M, Knoops L, Delahaye L, Kersten M J, Kibbelaar R E, Wessels L A, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25: 390–398
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvadó M T, Lopez C, Jaén J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350–5357
   PubMed Web of Science ®Google Scholar
• de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23: 6358–6363
   PubMed Web of Science ®Google Scholar
• Byers R J, Sakhina E, Jacob P, Glennie C, Hoyland J A, Menasce L, et al. Clinical quantitation of Immune Signature in Follicular Lymphoma by RT-PCR based gene expression profiling. Blood, [Epub Jan 3 2008]
   Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomised study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi J F, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up. Blood 2007; 110: 792, Abstract
   Web of Science ®Google Scholar
• Schulz H, Bohlius J F, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Institute 2007; 99: 706–714
   PubMed Web of Science ®Google Scholar
• Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007; 109: 2077–2082
   PubMed Web of Science ®Google Scholar
• Rohatiner A, Gregory W M, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
   PubMed Web of Science ®Google Scholar
• Haas R L, Poortmans P, de Jong D, Aleman B M, Dewit L G, Verheij M, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003; 21: 2474–2480
   PubMed Web of Science ®Google Scholar
• Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007; 110: 1116–1122
   PubMed Web of Science ®Google Scholar
• Du Y, Honeychurch J, Cragg M S, Bayne M, Glennie M J, Johnson P W, et al. Antibody-induced intracellular signalling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004; 103: 1485–1494
   PubMed Web of Science ®Google Scholar
• Fisher R, Kaminski M, Wahl R, Knox S, Zelenetz A, Vose J, et al. Tositumomab and Iodine-131 Tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low grade and transformed Non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565–7573
   PubMed Web of Science ®Google Scholar
• Wiseman G, Witzig T. Yttrium-90 Ibritumomab Tiuxetan induces long-term durable responses in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma. Cancer Biother Radiopharm 2005; 20: 185–188
   PubMed Web of Science ®Google Scholar
• Kaminski M, Tuck M, Estes J, Kolstad A, Ross C, Zasadny K, et al. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Eng J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Press O, Unger J, Braziel R, Maloney D, Miller T, LeBlanc M, et al. Phase II trial of CHOP chemotherapy followed by Tositumomab/Iodine I-131 Tositumomab for previously untreated follicular Non-Hodgkin's Lymphoma: five year follow-up of southwest oncology group protocol S9911. J Clin Oncol 2006; 24: 4143–4149
   PubMed Web of Science ®Google Scholar
• Leonard J, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman R, et al. Abbreviated chemotherapy with Fludarabine followed by tositumomab and Iodine 131 Tositumomab for untreated follicular lymphoma. J Clin Oncol 2005; 23: 5696–5704
   PubMed Web of Science ®Google Scholar
• Link B, Kaminiski M, Coleman M, Leonard J. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular Non-Hodgkin's lymphoma (NHL). J Clin Oncol 2004; 22: 6520
   Web of Science ®Google Scholar
• Shipley D, Greco F, Spigel R, Edwards D, Mayfield M, Yost K, et al. Rituximab with short duration chemotherapy followed by 90Y Ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2005; 23: 6577
   Google Scholar
• Hagenbeek A, Bischof-Delaloye A, Radford J A, Rohatiner A, Salles G, Van Hoof A, et al. 90Y-ibritumomab tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 First-line Indolent Trial (FIT) in 414 patients. Blood 2007; 110, (Pt 1 of 2):198a. Abstract 643
   Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926–4933
   PubMed Web of Science ®Google Scholar
• Deconinck E, Hunault M, Milpied N, Bernard M, Renaud M, Desablens B, et al. Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity—a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study. Biol Blood Marrow Transplant 2005; 11: 448–454
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Böck H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• Dreyling M, Forstpointner R, Gramatzki M, Böck H, Hänel M, Seymour J, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomised trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2006; 24: 7502
   Google Scholar
• van Oers M, Klasa R, Marcus R, Wolf M, Kimby E, Gascoyne R, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301
   PubMed Web of Science ®Google Scholar
• Hainsworth J, Litchy S, Shaffer D, Lackey V, Grimaldi M, Greco F. Maximising therapeutic benefit of Rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's Lymphoma—a randomised phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1094
   PubMed Web of Science ®Google Scholar
• Ghielmini G, Schmitz S F, Cogliatti S, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases EFS and response duration compared with the standard weekly×4 schedule. Blood 2004; 103: 4416–4423
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne R, Ryan T, Habermann T, Gordon L, et al. Maintenance Rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukaemia Group B. Blood 2005; 106: 349
   Google Scholar
• Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction [abstract]. Blood 2006; 108: 72a–229
   Web of Science ®Google Scholar